GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » LT-Debt-to-Total-Asset

Actelion (XSWX:ATLNE) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Actelion's long-term debt to total assests ratio for the quarter that ended in Mar. 2017 was 0.00.

Actelion's long-term debt to total assets ratio stayed the same from Mar. 2016 (0.00) to Mar. 2017 (0.00).


Actelion LT-Debt-to-Total-Asset Historical Data

The historical data trend for Actelion's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion LT-Debt-to-Total-Asset Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.08 - - -

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Actelion LT-Debt-to-Total-Asset Calculation

Actelion's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=0/2106.477
=0.00

Actelion's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2017 is calculated as

LT Debt to Total Assets (Q: Mar. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2017 )/Total Assets (Q: Mar. 2017 )
=0/2335.689
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Actelion LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Actelion's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines